# Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

> **NCT03672292** · PHASE2 · TERMINATED · sponsor: **Scynexis, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Invasive Pulmonary Aspergillosis

## Interventions

- **DRUG:** SCY-078
- **DRUG:** Voriconazole
- **OTHER:** Oral Placebo Tablets

## Key facts

- **NCT ID:** NCT03672292
- **Lead sponsor:** Scynexis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-22
- **Primary completion:** 2023-03-27
- **Final completion:** 2023-03-27
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Enrollment took longer than anticipated (slow enrollment during COVID).
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672292, "Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03672292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*